Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ScTIL210 in digestive system tumors
NCT05730361Phase 1Unknown
- Sponsor
- Peking University
- Start
- Feb 2023
- Primary completion
- May 2024
- Modality
- Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of ScTIL in digestive system neoplasm, sponsored by Peking University. Primary endpoint: Objective Response Rate at 12 weeks. Status: unknown.
02
Drugs
ScTIL
03
Conditions
digestive system neoplasm
Beyond the preview
Go deeper on NCT05730361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05730361.